Covalon Technologies (CVE:COV) Hits New 52-Week High at $3.26

Covalon Technologies Ltd. (CVE:COV)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$3.26 and last traded at C$3.10, with a volume of 140158 shares changing hands. The stock had previously closed at C$3.18.

Covalon Technologies Stock Performance

The company has a debt-to-equity ratio of 6.34, a quick ratio of 6.45 and a current ratio of 6.80. The business’s fifty day moving average price is C$2.29 and its 200-day moving average price is C$1.67. The stock has a market cap of C$78.94 million, a PE ratio of -26.75 and a beta of 0.66.

Covalon Technologies (CVE:COV) last released its earnings results on Wednesday, May 29th. The company reported C$0.06 earnings per share for the quarter. The company had revenue of C$8.41 million for the quarter. Covalon Technologies had a negative return on equity of 13.22% and a negative net margin of 10.57%. As a group, equities research analysts forecast that Covalon Technologies Ltd. will post 0.3 EPS for the current fiscal year.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.